Fibro test/fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: A meta-analysis

American Journal of Gastroenterology

Volumn 109, Issue 6, 2014, Pages 796-809

  Salkic, Nermin N ^a   Jovanovic, Predrag ^a   Hauser, Goran ^b   Brcic, Majda ^a  

^a UNIVERSITY CLINICAL CENTER TUZLA   (Bosnia and Herzegovina)

^b KBC RIJEKA   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD SAMPLING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST KIT; META ANALYSIS; MIXED INFECTION; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; BLOOD; LIVER; LIVER FUNCTION TEST; METABOLISM; PATHOLOGY; REPRODUCIBILITY; VIROLOGY;

ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN;

ALPHA-MACROGLOBULINS; APOLIPOPROTEIN A-I; BILIRUBIN; BIOLOGICAL MARKERS; GAMMA-GLUTAMYLTRANSFERASE; HAPTOGLOBINS; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84902113013     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.21     Document Type: Review

References (69)

1. WHO fact sheet No 204: Hepatitis B. World Health Organization;July 2013. Available from http://www.who.int/mediacentre/factsheets/fs204/en/ index.html
2. Sebastiani G, Alberti A. Non invasive fi brosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006;12;3682-94. (Pubitemid 43950946
3. European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012;57;167-85
4. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34;1225-41. (Pubitemid 33096596
5. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: Results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000;32;477-81
6. Terjung B, Lemnitzer I, Dumoulin FL, et al. Bleeding complications aft er percutaneous liver biopsy. An analysis of risk factors. Digestion 2003;67;138-45
7. West J, Card TR. Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology 2010;139;1230-7
8. Brunetti E, Silini E, Pistorio A, et al. Coarse vs. fi ne needle aspiration biopsy for the assessment of diff use liver disease from hepatitis C virus-related chronic hepatitis. J Hepatol 2004;40;501-6. (Pubitemid 38230853
9. Colloredo G, Guido M, Sonzogni A, et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: The smaller the sample, the milder the disease. J Hepatol 2003;39;239-44. (Pubitemid 36920560
10. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005;41;257-64. (Pubitemid 40165369
11. Cast éra L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. YGAST 2012;142;1293-1302.e4
12. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20;15-20
13. Pinzani M, Vizzutti F, Arena U, et al. Technology Insight: Noninvasive assessment of liver fi brosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol 2008;5;95-106. (Pubitemid 351234279
14. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fi brosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001;357;1069-75. (Pubitemid 32322537
15. Poynard T, Imbert-Bismut F, Munteanu M, et al. Overview of the diagnostic value of biochemical markers of liver fi brosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004;3;8
16. Cales P, Veillon P, Konate A, et al. Reproducibility of blood tests of liver fi brosis in clinical practice. Clin Biochem 2008;41;10-8. (Pubitemid 350216822
17. Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004;50;1344-55. (Pubitemid 38970641
18. Rockey DC, Bissell DM. Noninvasive measures of liver fi brosis. Hepatology 2006;43;S113-20
19. Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fi brosis. Gastroentérol Clin Biol 2008;32;22-39
20. Poynard T, Lassailly G, Diaz E, et al. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: Meta analysis of individual patient data. PloS One 2012;7;e30325
21. Poynard T, Morra R, Halfon P, et al. Meta-Analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007;7;40
22. Poynard T, Ngo Y, Munteanu M, et al. Noninvasive markers of hepatic fi brosis in chronic hepatitis B. Curr Hepat Rep 2011;10;87-97
23. Poynard T, Ngo Y, Perazzo H, et al. Prognostic value of liver fi brosis biomarkers: A meta-Analysis. Gastroenterol Hepatol 2011;7;445-54
24. Shaheen AAM, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fi brosis: A systematic review of diagnostic test accuracy. Am J Gastroenterols 2007;102;2589-600. (Pubitemid 47631778
25. Macaskill P, Gatsonis C, Deeks JJ, et al. Chapter 10: Analysing and Presenting Results. In Deeks JJ, Bossuyt PM, Gatsonis C (eds). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0 The Cochrane Collaboration 2010
26. Bossuyt PM, Leefl ang MM. Chapter 6: Developing Criteria for Including Studies. In: Deeks JJ, Bossuyt PM, Gatsonis C (eds). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 0.4 [updated September 2008]: The Cochrane Collaboration, 2008
27. Whiting PF, Rutjes AW, Westwood ME;et al. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155;529-36
28. Reitsma JB, Rutjes AWS, Whiting P, et al. Chapter 9: Assessing methodological quality. In: Deeks JJ, Bossuyt PM, Gatsonis C (eds). Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy Version 1.0.0: The Cochrane Collaboration, 2009
29. Whiting P. The development of QUADAS-2: A revised tool for the quality assessment of diagnostic test accuracy studies 2007. Available from http:// www.bris.ac.uk/quadas/resources/.
30. Poynard T, Halfon P, Castéra L, et al. Standardization of ROC curve areas for diagnostic evaluation of liver fi brosis markers based on prevalences of fi brosis stages. Clin Chem 2007;53;1615-22. (Pubitemid 47340057
31. Takwoingi Y, Deeks JJ. MetaDAS: A SAS macro for meta-Analysis of diagnostic accuracy studies. User Guide Version 1.3 2010 Available from: Http://srdta.cochrane.org/soft ware-development
32. Martinez SM, Crespo G, Navasa M, et al. Noninvasive assessment of liver fi brosis. Hepatology 2011;53;325-35
33. Poynard T, Bedossa P, Opolon P. Natural history of liver fi brosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349;825-32. (Pubitemid 27129209
34. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size eff ects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58;882-93. (Pubitemid 41115772
35. Anastasiou J, Alisa A, Virtue S, et al. Noninvasive markers of fi brosis and infl ammation in clinical practice: Prospective comparison with liver biopsy. Eur J Gastroenterol Hepatol 2010;22;474-80
36. Boursier J, Vergniol J, Sawadogo A, et al. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fi brosis. Liver Int 2009;29;1507-15
37. Chen J, Liu C, Chen H, et al. Study on noninvasive laboratory tests for fi brosis in chronic HBV infection and their evaluation. J Clin Lab Anal 2013;27;5-11
38. de Lédinghen V, Vergniol J, Barthe C, et al. Non-invasive tests for fi brosis and liver stiff ness predict 5-year survival of patients chronically infected with hepatitis B virus. Alim Pharmacol Ther 2013;37;979-88
39. Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fi brosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study). J Hepatol 2010;53;1013-21
40. Dolmazashvili E, Zhamutashvili M, Svanidze M, et al. Fibroscan and FibroTest/FibroMax to assess liver fi brosis/cirrhosis in patients with chronic HBV and HCV infection in Georgia. Georgian Med News 2008;165;83-7
41. Friedrich-Rust M, Rosenberg W, Parkes J, et al. Comparison of ELF, Fibro-Test and FibroScan for the non-invasive assessment of liver fi brosis. BMC Gastroenterol 2010;10;103
42. Friedrich-Rust M, Schwarz A, Ong M, et al. Real-Time tissue elastography versus FibroScan for noninvasive assessment of liver fi brosis in chronic liver disease. Ultraschall Med 2009;30;478-84
43. Mallet V, Dhalluin-Venier V, Roussin C, et al. The accuracy of the FIB-4 index for the diagnosis of mild fi brosis in chronic hepatitis B. Alim Pharmacol Ther 2009;29;409-15
44. Uyar C, Akcam FZ, Ciris M, et al. Comparison of FibroTest-ActiTest with histopathology in demonstrating fi brosis and necroinfl ammatory activity in chronic hepatitis B and C. Indian J Pathol Microbiol 2010;53;470-5
45. Cassinotto C, Lapuyade B, A ï t-Ali A, et al. Liver fi brosis: Noninvasive assessment with acoustic radiation force impulse elastography-comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease. Radiology 2013;269;283-92
46. Myers RP, Tainturier M-H, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003;39;222-30. (Pubitemid 36920558
47. Zhao L, Xu D, Lu Z, et al. Validation of Fibrotest to diagnose liver fi brosis to patients with chronic hepatitis B. Chinese J Pract Int Med 2007;27;1274-7
48. Sebastiani G, Vario A, Guido M, et al. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fi brosis in chronic hepatitis B. World J Gastroenterol 2007;13;525-31. (Pubitemid 46210918
49. Gui H-L, Xie Q, Wang H. FibroTest-ActiTest for predicting liver fi brosis and infl ammatory activity in Chinese patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi 2008;16;897-901
50. Poynard T, Ngo Y, Marcellin P, et al. Impact of adefovir dipivoxil on liver fi brosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. J Viral Hepat 2009;16;203-13
51. Bottero J, Lacombe K, Guéchot J, et al. Performance of 11 biomarkers for liver fi brosis assessment in HIV/HBV co-infected patients. J Hepatol 2009;50;1074-83
52. Bonnard P, SombiéR, Lescure F-X, et al. Comparison of elastography, serum marker scores, and histology for the assessment of liver fi brosis in hepatitis B virus (HBV)-infected patients in Burkina Faso. Am J Trop Med Hyg 2010;82;454-8
53. Castéra L, Bernard P-H, Le Bail B, et al. Transient elastography and biomarkers for liver fi brosis assessment and follow-up of inactive hepatitis B carriers. Alim Pharmacol Ther 2011;33;455-65
54. Mbaye PS, Sarr A, Sire J-M, et al. Liver stiff ness measurement and biochemical markers in senegalese chronic Hepatitis B patients with normal ALT and high viral load. PloS one 2011;6;e22291
55. Miailhes P, Pradat P, Chevallier M, et al. Profi ciency of transient elastography compared to liver biopsy for the assessment of fi brosis in HIV/HBVcoinfected patients. J Viral Hepat 2011;18;61-9
56. Stibbe KJM, Verveer C, Francke J, et al. Comparison of non-invasive assessment to diagnose liver fi brosis in chronic hepatitis B and C patients. Scand J Gastroenterol 2011;46;962-72
57. Raft opoulos SC, George J, Bourliere M, et al. Comparison of noninvasive models of fi brosis in chronic hepatitis B. Hepatol Int 2011;6;457-67
58. Sebastiani G, Castéra L, Halfon P, et al. The impact of liver disease aetiology and the stages of hepatic fi brosis on the performance of non-invasive fi brosis biomarkers: An international study of 2411 cases. Alim Pharmacol Ther 2011;34;1202-16
59. Kim BK, Kim HS, Park JY, et al. Prospective validation of ELF test in comparison with Fibroscan and FibroTest to predict liver fi brosis in Asian subjects with chronic hepatitis B. PloS One 2012;7;e41964
60. Kim BK, Kim SU, Kim HS, et al. Prospective validation of FibroTest in comparison with liver stiff ness for predicting liver fi brosis in Asian subjects with chronic hepatitis B. PloS One 2012;7;e35825
61. Park MS, Kim BK, Cheong JY, et al. Discordance between liver biopsy and FibroTest in assessing liver fi brosis in chronic hepatitis B. PloS One 2013;8;e55759
62. Dinnes J, Deeks J, Kirby J, et al. A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess 2005;9;1-113, iii
63. Regev A, Berho M, Jeff ers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97;2614-8
64. Poynard T, Munteanu M, Deckmyn O, et al. Validation of liver fi brosis biomarker (FibroTest) for assessing liver fi brosis progression: Proof of concept and fi rst application in a large population. J Hepatol 2012;100;541-8
65. Mehta SH, Lau B, Afdhal NH, et al. Exceeding the limits of liver histology markers. J Hepatol 2009;50;36-41
66. Maharaj B, Maharaj RJ, Leary WP, et al. Sampling variability and its infl uence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986;1;523-5. (Pubitemid 16138427
67. Halfon P, Bacq Y, De Muret A, et al. Comparison of test performance profi le for blood tests of liver fi brosis in chronic hepatitis C. J Hepatol 2007;46;395-402. (Pubitemid 46201720
68. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fi brosis in chronic hepatitis C. Hepatology 2003;38;1449-57. (Pubitemid 37466971
69. Leefl ang MM, Moons KG, Reitsma JB, et al. Bias in sensitivity and specifi-city caused by data-driven selection of optimal cutoff values: Mechanisms, magnitude, and solutions. Clin Chem 2008;54;729-37